cytochrome P450 family 2 subfamily R member 1Genealiases: []
Q-omics provides the consensus-scored CYP2R1 profile across patient tissues and cancer cell-line models. CYP2R1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, CYP2R1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CYP2R1 RNA expression shows 20,343 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, KIRC, and ACC as cancer lineages where CYP2R1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP2R1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP2R1 survival associations across molecular data types. CYP2R1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP2R1 RNA expression–survival associations across cancer types. High CYP2R1 expression shows unfavorable associations in KICH, ACC, UCEC and KIRC, but favorable associations in READ and BRCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for CYP2R1 RNA expression.
This table summarizes CYP2R1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CYP2R1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP2R1 shows higher tumor expression in KIRC, LIHC, KIRP, CHOL, BLCA and STAD. The KIRC box plot shows higher CYP2R1 RNA expression in tumor versus normal tissue (log2 FC = +0.539, t-test p < 0.001).
This table shows molecular features associated with CYP2R1 in patient tissues and cancer cell lines. In patient samples, CYP2R1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP2R1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
